HS2.DE
Henry Schein, Inc. [HS2.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HS2.DE Stock Summary
Top 10 Correlated ETFs
HS2.DE
Top 10 Correlated Stocks
HS2.DE
In the News
HS2.DE Financial details
Company Rating
Strong Buy
Market Cap
5.65B
Income
458M
Revenue
12.6B
Book val./share
27.2
Cash/share
1.05
Dividend
-
Dividend %
-
Employees
19K
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
21.21
Forward P/E
10.85
PEG
-8.86
P/S
0.48
P/B
2.73
P/C
66.53
P/FCF
11.45
Quick Ratio
0.71
Current Ratio
1.72
Debt / Equity
0.53
LT Debt / Equity
0.4
-
-
EPS (TTM)
3.43
EPS next Y
6.44
EPS next Q
-
EPS this Y
-12.42%
EPS next Y
87.78%
EPS next 5Y
87.78%
EPS last 5Y
2.39%
Revenue last 5Y
-0.86%
Revenue Q/Q
1.31%
EPS Q/Q
16.3%
-
-
-
-
SMA20
-1.41%
SMA50
-2.78%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
5%
ROE
13%
ROC
0.11%
Gross Margin
31%
Oper. Margin
6%
Profit Margin
4%
Payout
-
Shs Outstand
82.07M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
67.88-82.63
52W High
-14.8%
52W Low
+4.27%
RSI
51
Rel Volume
-
Avg Volume
-
Volume
10
Perf Week
1.36%
Perf Month
-0.77%
Perf Quarter
-
Perf Half Y
-4.5%
-
-
-
-
Beta
-
-
-
Volatility
0.48%, 0.91%
Prev Close
-0.51%
Price
69.86
Change
-0.51%
HS2.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 86.48 | 67.56 | 71.01 | 88.52 | 92.95 | |
| Net income per share | 3.51 | 3.52 | 2.83 | 4.51 | 3.95 | |
| Operating cash flow per share | 4.49 | 4.42 | 4.2 | 5.07 | 4.42 | |
| Free cash flow per share | 3.89 | 3.91 | 3.86 | 4.5 | 3.72 | |
| Cash per share | -1.15 | 0.72 | 2.96 | 0.84 | 0.86 | |
| Book value per share | 19.4 | 20.28 | 23.5 | 24.45 | 25.33 | |
| Tangible book value per share | 0.9 | 4.02 | 7.02 | 3.86 | 8.75 | |
| Share holders equity per share | 19.4 | 20.28 | 23.5 | 24.45 | 25.33 | |
| Interest debt per share | 13.38 | 7.1 | 7.32 | 8.88 | 11.33 | |
| Market cap | 8.91B | 8.45B | 9.4B | 10.96B | 10.93B | |
| Enterprise value | 10.8B | 9.34B | 9.98B | 12.06B | 12.31B | |
| P/E ratio | 16.63 | 16.23 | 23.29 | 17.36 | 20.32 | |
| Price to sales ratio | 0.68 | 0.85 | 0.93 | 0.88 | 0.86 | |
| POCF ratio | 13.02 | 12.92 | 15.7 | 15.44 | 18.16 | |
| PFCF ratio | 15 | 14.63 | 17.1 | 17.38 | 21.6 | |
| P/B Ratio | 3.01 | 2.82 | 2.81 | 3.2 | 3.17 | |
| PTB ratio | 3.01 | 2.82 | 2.81 | 3.2 | 3.17 | |
| EV to sales | 0.82 | 0.94 | 0.99 | 0.97 | 0.97 | |
| Enterprise value over EBITDA | 9.62 | 10.04 | 13.16 | 11.21 | 11.11 | |
| EV to operating cash flow | 15.77 | 14.29 | 16.67 | 16.99 | 20.45 | |
| EV to free cash flow | 18.18 | 16.17 | 18.15 | 19.12 | 24.33 | |
| Earnings yield | 0.06 | 0.06 | 0.04 | 0.06 | 0.05 | |
| Free cash flow yield | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | |
| Debt to equity | 0.66 | 0.33 | 0.3 | 0.36 | 0.43 | |
| Debt to assets | 0.23 | 0.14 | 0.13 | 0.14 | 0.17 | |
| Net debt to EBITDA | 1.68 | 0.96 | 0.77 | 1.02 | 1.25 | |
| Current ratio | 1.3 | 1.58 | 1.66 | 1.67 | 1.79 | |
| Interest coverage | 9.56 | 14.14 | 12.94 | 30.86 | 16.98 | |
| Income quality | 1.22 | 0.91 | 1.43 | 1.07 | 1.06 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.28 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.4 | 0.42 | 0.38 | 0.42 | 0.4 | |
| Capex to operating cash flow | -0.13 | -0.12 | -0.08 | -0.11 | -0.16 | |
| Capex to revenue | -0.01 | -0.01 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.44 | -0.41 | -0.26 | -0.38 | -0.45 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
| Graham number | 39.14 | 40.1 | 38.7 | 49.79 | 47.47 | |
| ROIC | 0.12 | 0.13 | 0.09 | 0.13 | 0.11 | |
| Return on tangible assets | 0.11 | 0.13 | 0.08 | 0.13 | 0.1 | |
| Graham Net | -19.3 | -11.95 | -10.82 | -16.28 | -12.91 | |
| Working capital | 956.39M | 1.19B | 1.51B | 1.54B | 1.76B | |
| Tangible asset value | 137.25M | 594.76M | 1B | 541.42M | 1.19B | |
| Net current asset value | -783.52M | -294.46M | 3.27M | -573.86M | 52M | |
| Invested capital | 0.66 | 0.33 | 0.3 | 0.36 | 0.43 | |
| Average receivables | 1.54B | 1.42B | 1.34B | 1.44B | 1.45B | |
| Average payables | 1.19B | 1.05B | 942.96M | 1.03B | 1.03B | |
| Average inventory | 1.95B | 1.7B | 1.47B | 1.69B | 1.91B | |
| Days sales outstanding | 44.34 | 45.55 | 51.39 | 42.73 | 41.62 | |
| Days payables outstanding | 46.63 | 46.6 | 50.25 | 44.07 | 41.57 | |
| Days of inventory on hand | 74.88 | 75.64 | 75.58 | 77.82 | 81.27 | |
| Receivables turnover | 8.23 | 8.01 | 7.1 | 8.54 | 8.77 | |
| Payables turnover | 7.83 | 7.83 | 7.26 | 8.28 | 8.78 | |
| Inventory turnover | 4.87 | 4.83 | 4.83 | 4.69 | 4.49 | |
| ROE | 0.18 | 0.17 | 0.12 | 0.18 | 0.16 | |
| Capex per share | -0.59 | -0.52 | -0.34 | -0.56 | -0.71 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 22.06 | 22.62 | 24.54 | 23.29 | 23.68 | |
| Net income per share | 1.16 | 1.11 | 0.34 | 0.92 | 1.07 | |
| Operating cash flow per share | 1.14 | 0.72 | 1.85 | 0.21 | 2.09 | |
| Free cash flow per share | 0.97 | 0.55 | 1.64 | -0.03 | 1.81 | |
| Cash per share | 0.79 | 0.91 | 0.85 | 0.96 | 1.05 | |
| Book value per share | 26.17 | 26.63 | 25.09 | 26.43 | 27.2 | |
| Tangible book value per share | 10.03 | 9.61 | 8.67 | 9.38 | 7.59 | |
| Share holders equity per share | 26.17 | 26.63 | 25.09 | 26.43 | 27.2 | |
| Interest debt per share | 8.86 | 10.32 | 11.02 | 12.74 | 14.52 | |
| Market cap | 10.56B | 9.14B | 11.03B | 10.48B | 10.56B | |
| Enterprise value | 11.66B | 10.41B | 12.41B | 12.01B | 12.3B | |
| P/E ratio | 16.51 | 15.24 | 58.7 | 21.65 | 18.86 | |
| Price to sales ratio | 3.49 | 2.98 | 3.27 | 3.42 | 3.41 | |
| POCF ratio | 67.29 | 93.31 | 43.44 | 388.1 | 38.54 | |
| PFCF ratio | 79.43 | 123.57 | 49.04 | -2.62K | 44.55 | |
| P/B Ratio | 2.94 | 2.53 | 3.2 | 3.02 | 2.97 | |
| PTB ratio | 2.94 | 2.53 | 3.2 | 3.02 | 2.97 | |
| EV to sales | 3.85 | 3.39 | 3.68 | 3.93 | 3.97 | |
| Enterprise value over EBITDA | 42.26 | 37.44 | 49.07 | 46.38 | 43.63 | |
| EV to operating cash flow | 74.29 | 106.22 | 48.88 | 444.88 | 44.9 | |
| EV to free cash flow | 87.7 | 140.66 | 55.18 | -3K | 51.92 | |
| Earnings yield | 0.02 | 0.02 | 0 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0.02 | 0 | 0.02 | |
| Debt to equity | 0.34 | 0.38 | 0.43 | 0.48 | 0.53 | |
| Debt to assets | 0.15 | 0.16 | 0.17 | 0.19 | 0.21 | |
| Net debt to EBITDA | 3.99 | 4.55 | 5.45 | 5.92 | 6.19 | |
| Current ratio | 1.83 | 1.84 | 1.79 | 1.82 | 1.72 | |
| Interest coverage | 24.44 | 19.18 | 11.82 | 12.5 | 10.58 | |
| Income quality | 0.94 | 0.6 | 4.98 | 0.21 | 1.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.41 | 0.41 | 0.4 | 0.4 | 0.44 | |
| Capex to operating cash flow | -0.15 | -0.24 | -0.11 | -1.15 | -0.14 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.45 | -0.46 | -0.56 | -0.6 | -0.63 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Graham number | 26.19 | 25.74 | 13.9 | 23.4 | 25.58 | |
| ROIC | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | |
| Return on tangible assets | 0.03 | 0.03 | 0.01 | 0.02 | 0.03 | |
| Graham Net | -10.45 | -11.53 | -12.78 | -12.85 | -15.13 | |
| Working capital | 1.71B | 1.81B | 1.76B | 1.78B | 1.64B | |
| Tangible asset value | 1.38B | 1.3B | 1.19B | 1.23B | 993M | |
| Net current asset value | 278M | 231M | 52M | 77M | -229M | |
| Invested capital | 0.34 | 0.38 | 0.43 | 0.48 | 0.53 | |
| Average receivables | 1.43B | 1.46B | 1.47B | 1.46B | 1.47B | |
| Average payables | 907.5M | 929M | 980.5M | 929.5M | 836M | |
| Average inventory | 1.85B | 1.82B | 1.89B | 1.94B | 1.88B | |
| Days sales outstanding | 41.85 | 44.22 | 38.5 | 43.24 | 42.62 | |
| Days payables outstanding | 38.89 | 40 | 38.09 | 36.75 | 34.6 | |
| Days of inventory on hand | 78.69 | 76 | 74.48 | 82.44 | 78.06 | |
| Receivables turnover | 2.15 | 2.04 | 2.34 | 2.08 | 2.11 | |
| Payables turnover | 2.31 | 2.25 | 2.36 | 2.45 | 2.6 | |
| Inventory turnover | 1.14 | 1.18 | 1.21 | 1.09 | 1.15 | |
| ROE | 0.04 | 0.04 | 0.01 | 0.03 | 0.04 | |
| Capex per share | -0.17 | -0.18 | -0.21 | -0.24 | -0.28 |
HS2.DE Frequently Asked Questions
What is Henry Schein, Inc. stock symbol ?
Henry Schein, Inc. is a US stock , located in Melville of New york and trading under the symbol HS2.DE
What is Henry Schein, Inc. stock quote today ?
Henry Schein, Inc. stock price is $69.86 today.
Is Henry Schein, Inc. stock public?
Yes, Henry Schein, Inc. is a publicly traded company.
Company Profile
- Market Capitalization 5.65B
- Employee 19K
- CEO Mr. Stanley Bergman
- Headquarters Melville,NEW YORK,US
- IPO Date 2007-07-30
-
Website
https://www.henryschein.com/ 
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. The company is headquartered in Melville, New York and currently employs 18,000 full-time employees. The firm operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners. The firm provides its services to dental practitioners and laboratories, and physician practices, as well as government and institutional healthcare clinics.
